<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159210</url>
  </required_header>
  <id_info>
    <org_study_id>220901</org_study_id>
    <secondary_id>2010-019250-41</secondary_id>
    <nct_id>NCT01159210</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal</brief_title>
  <official_title>An International, Multi-centre, Prospective, Open-Label, Non-Randomised, Uncontrolled Study to Assess the Efficacy and Safety of Prothromplex Total in Oral Anticoagulant Reversal in Patients With Acquired Deficiency of Prothrombin Complex Coagulation Factors (II, VII, IX, X)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy and safety of Prothromplex Total as a&#xD;
      treatment for the immediate reversal of oral anticoagulant therapy with vitamin K antagonists&#xD;
      in patients with acquired deficiency of prothrombin complex coagulation factors (II, VII, IX,&#xD;
      X). Upon enrolment, subjects will receive Prothromplex Total for the treatment of acute&#xD;
      bleeding due to oral anticoagulants or for the prevention of excessive bleeding during the&#xD;
      interventional procedure (Day 1). Additional doses of Prothromplex Total may be administered&#xD;
      at the discretion of the investigator. Efficacy and safety assessments will be performed&#xD;
      during a period of 72 (± 4) hours after administration of the last dose of Prothromplex Total&#xD;
      or until discharge from hospital, whichever occurs first.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2010</start_date>
  <completion_date type="Actual">April 7, 2012</completion_date>
  <primary_completion_date type="Actual">April 7, 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve normalisation of International normalised ratio (INR) to &lt;= 1.3 within 30 (±5) minutes post administration of Prothromplex Total</measure>
    <time_frame>within 35 minutes after administration of study drug</time_frame>
  </primary_outcome>
  <enrollment type="Actual">61</enrollment>
  <condition>Prothrombin Complex Factor Deficiency</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)</intervention_name>
    <description>Intravenous infusion; regimen is guided by the pre-treatment international normalised ratio (INR); dosage and duration of replacement therapy depend on the severity of the disorder, on the location and extent of bleeding and on the patient´s clinical condition.</description>
    <other_name>Prothromplex Total</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is at least 16 years or older at enrolment with acquired deficiency of&#xD;
             prothrombin complex coagulation factors (II, VII, IX, X), due to oral anticoagulation&#xD;
             with vitamin K antagonists (e.g. coumarin, warfarin), requiring reversal of oral&#xD;
             anticoagulation for urgent surgery, or invasive procedure or acute bleeding episode&#xD;
&#xD;
          -  Subject or parent/legally authorised representative has provided written informed&#xD;
             consent&#xD;
&#xD;
          -  Subject has INR &gt;= 2,0 at screening&#xD;
&#xD;
          -  Subject is willing and able to comply with the requirements of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has laboratory and/or clinical symptoms which are clearly indicative of overt&#xD;
             disseminated intravascular coagulation (DIC)&#xD;
&#xD;
          -  Subject has been treated with whole blood, fresh frozen plasma (FFP), or platelets&#xD;
             within 6 hours prior to study enrolment&#xD;
&#xD;
          -  Subject has a hypersensitivity to prothrombin complex concentrate (PCC) constituents&#xD;
             (including heparin-induced thrombocytopenia)&#xD;
&#xD;
          -  Subject has blood loss of &gt;= 5 units of blood&#xD;
&#xD;
          -  Subject has hereditary thrombophilia or bleeding disorder&#xD;
&#xD;
          -  Subject has a life expectancy of &lt; 3 months&#xD;
&#xD;
          -  Subject has been on oral anticoagulant treatment for a period of &lt; 4 weeks for the&#xD;
             treatment of a thrombotic event such as deep vein thrombosis or pulmonary embolism&#xD;
&#xD;
          -  Subject has an acute ischemic cardiovascular disorder&#xD;
&#xD;
          -  Subject has or is suspected to have sepsis&#xD;
&#xD;
          -  Subject with acute or chronic liver failure (hepatic cirrhosis Child-PUGH score C)&#xD;
&#xD;
          -  Subject has participated in another clinical study involving an investigational&#xD;
             product (IP) or investigational device within 30 days prior to enrolment or is&#xD;
             scheduled to participate in another clinical study involving an IP or investigational&#xD;
             device during the course of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin I (University Hospital for Internal Medicine I), Allgemeines Krankenhaus der Stadt Wien (General Hospital Vienna)</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhügel</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DEOEC, University of Debrecen, Medical and Health Science Centre</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent György Korhaz</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veszprem Megyei Csolnoky Korhaz Nonprofit Zrt., Belgyógyászati Centrum, Haematológiai Részleg</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

